Citigroup’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-3,035
Closed -$74K 7818
2017
Q4
$74K Buy
+3,035
New +$58.3K ﹤0.01% 5895
2017
Q3
Sell
-81
Closed -$1K 7605
2017
Q2
$1K Sell
81
-268
-77% -$3.73K ﹤0.01% 7293
2017
Q1
$5K Sell
349
-4,762
-93% -$76.5K ﹤0.01% 6835
2016
Q4
$97K Buy
5,111
+4,452
+676% +$85.4K ﹤0.01% 5796
2016
Q3
$15K Buy
+659
New +$12.4K ﹤0.01% 6372
2016
Q2
Sell
-3,823
Closed -$70K 7704
2016
Q1
$70K Buy
3,823
+3,822
+382,200% +$61.8K ﹤0.01% 5918
2015
Q4
$0 Hold
1
﹤0.01% 8078
2015
Q3
$0 Sell
1
-69
-99% -$1.54K ﹤0.01% 8020
2015
Q2
$2K Sell
70
-1,495
-96% -$37.8K ﹤0.01% 7203
2015
Q1
$35K Buy
+1,565
New +$33.8K ﹤0.01% 5760

Citigroup's ENTL Position: Q1 2018 in Review

Citigroup sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 3,035 shares — an estimated $74K sold.

Citigroup first reported a position in ENTL in Q1 2015 and held it in 10 quarters. The position peaked at $97K in Q4 2016. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.

  • Citigroup reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Citigroup sold 3,035 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $74K.
  • Citigroup first reported a position in Entellus Medical, Inc. Common Stock in Q1 2015 and held it in 10 quarters.
  • Citigroup's Entellus Medical, Inc. Common Stock position peaked at $97K in Q4 2016.
  • 0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.

Based on Citigroup's 13F filing for Q1 2018, filed 11 May 2018.